RGC (Regencell Bioscience Holdings) Moat Score: 2/10 (As of Jun. 28, 2026)


RGC Regencell Bioscience Holdings Ltd RGC
34 GF Score
Price $6.36
! 2 Warning Signs
View Full Analysis

What is Regencell Bioscience Holdings Moat Score?

Regencell Bioscience Holdings RGC -13.25% 34 Moat Score is 2 as of Jun. 28, 2026. GuruFocus rates RGC with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,033 Drug Manufacturers companies, Regencell Bioscience Holdings ranks better than 81.7% on this metric.

Regencell Bioscience Holdings has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Regencell Bioscience Holdings has No Moat: RGC operates in a niche bioscience market with limited competitive advantages. It lacks significant intellectual property, brand strength, or cost advantages, and its market presence is not substantial enough to create a durable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Regencell Bioscience Holdings might have No Moat - Very weak/transient advantages.

Regencell Bioscience Holdings  (NAS:RGC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Regencell Bioscience Holdings Moat Score Related Terms

RGC vs ELAN, NBIX, ALKS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Moat Score falls into.


RGC
34GF Score
Regencell Bioscience Holdings Ltd RGC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Regencell Bioscience Holdings (RGC) has a Moat Score of 2 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Regencell Bioscience Holdings ranks #189 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 18.3%.
Is Regencell Bioscience Holdings' Moat Score too high?
Regencell Bioscience Holdings' current Moat Score is 2. Based on the distribution chart, Regencell Bioscience Holdings ranks #189 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Regencell Bioscience Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' Moat Score compare to ELAN and NBIX?
According to the Drug Manufacturers industry distribution chart, Regencell Bioscience Holdings ranks #189 out of 1033 companies for Moat Score. This places Regencell Bioscience Holdings in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Regencell Bioscience Holdings's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current Moat Score of 2. The current Moat Score is 2. Regencell Bioscience Holdings' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current Moat Score is 2 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regencell Bioscience Holdings Business Description

Address 29 Leighton Road, 9th Floor, Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
34GF Score

Get the complete analysis for RGC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.36
Price